Drugs / CSL300
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07619820 | Jun 2026 → Aug 2027 expected | end stage renal failure | CSL Behring | Recruiting | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT05485961 | Oct 2022 → May 2029 expected | end stage renal failure | CSL Behring | Recruiting | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSL300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05485961 ↗ |
| Known as | Clazakizumab | “A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)” NCT07619820 ↗ |
| Action | Inhibit | “humanized anti-interleukin 6 (anti-IL-6) monoclonal antibody (mAb).” NCT07619820 ↗ |
| Modality | Monoclonal antibody | “CSL300 is a humanized anti-interleukin 6 (anti-IL-6) monoclonal antibody (mAb).” NCT07619820 ↗ |
| Route | Intravenous | “as a slow intravenous (IV) bolus” NCT07619820 ↗ |